Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
What is EGRIFTA SV and how is it used?
The long-term safety of EGRIFTA SV on the heart and blood vessels (cardiovascular) is not known.
EGRIFTA SV is not for weight loss management.
It is not known whether taking EGRIFTA SV helps improve how well you take (compliance with) antiretroviral medicines.
It is not known if EGRIFTA SV is safe and effective in children.
What are the possible side effects of EGRIFTA SV?
EGRIFTA SV may cause serious side effects, including:
The most common side effects of EGRIFTA SV include:
These are not all the possible side effects of EGRIFTA SV. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088.
EGRIFTA SV contains tesamorelin (as the acetate salt), a human growth hormone-releasing factor (GRF) analog. The peptide precursor of tesamorelin acetate is produced synthetically and is comprised of the 44 amino acid sequence of human GRF. Tesamorelin acetate is made by attaching a hexenoyl moiety, a C6 chain with a double bond at position 3, to the tyrosine residue at the N-terminal part of the molecule. The molecular formula of tesamorelin acetate is C221H366N72O67S • x C2H4O2(x ≈ 7) and its molecular weight (free base) is 5135.9 Daltons. The structural formula of tesamorelin acetate is:
 |
EGRIFTA SV is a sterile, white to off-white, preservative-free lyophilized powder for subcutaneous injection. After reconstitution with the supplied diluent (Sterile Water for Injection, USP), the solution is clear and colorless. Each single-dose vial of EGRIFTA SV contains 2 mg of tesamorelin acetate and the following inactive ingredients: 20 mg mannitol, USP, 10 mg sucrose, NF, 0.78 mg histidine, USP and 0.05 mg polysorbate 20, NF.
EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
EGRIFTA SV for injection is supplied in a single-dose 2 mg vial as a white to off-white lyophilized powder and a diluent of 10 mL of Sterile Water for Injection, USP.
EGRIFTA SV for injection is supplied as a white to off-white lyophilized powder in a 2 mg singledose vial with a diluent of 10 mL vial of Sterile Water for Injection, USP.
EGRIFTA SV (NDC 62064-241-30) is available in a package comprised of two boxes, containing 30 (thirty) 2 mg single-dose vials of EGRIFTA SV in the Medication Box and 30 single-dose 10 mL bottles of Sterile Water for Injection, USP diluent with a 30-day supply of disposable syringes and needles in the Injection Box.
Protect EGRIFTA SV from light and keep in the original box until time of use. Store EGRIFTA SV 2 mg/vial up to 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Store the Sterile Water for Injection, USP, syringes and needles at controlled room temperature of 20°C to 25°C (68°F to 77°F).
Distributed by: Theratechnologies Inc., Montréal, Québec, Canada H3A 1T8. Revised: Oct 2019
The following important adverse reactions are also described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of EGRIFTA SV (2 mg/vial formulation) has been established based on clinical trials conducted with EGRIFTA (1 mg/vial formulation). Adverse reactions for the 1.4 mg dose (2 mg/vial formulation) of EGRIFTA SV are expected to be similar to those observed with the 2 mg dose (1 mg/vial formulation) of EGRIFTA [see CLINICAL PHARMACOLOGY].
Seven hundred and forty (740) HIV-infected patients with lipodystrophy and excess abdominal fat were treated with EGRIFTA in clinical trials; of these, 543 received EGRIFTA during the initial 26-week placebo-controlled phase.
The most commonly reported adverse reactions were hypersensitivity reactions (e.g., rash, urticaria), edema-related reactions (e.g., arthralgia, extremity pain, peripheral edema, and carpal tunnel syndrome), hyperglycemia, and injection site reactions (injection site erythema, pruritus, pain, urticaria, irritation, swelling, and hemorrhage).
Adverse reactions that occurred more frequently with EGRIFTA relative to placebo and had an incidence ≥1% during the first 26 weeks across all studies are presented in Table 1.
Table 1: Adverse Reactions Reported in ≥ 1% and More Frequent in EGRIFTA -treated than Placebo Patients during the 26-Week Phase (Combined Studies )
| Preferred Term | Placebo (N=263) | EGRIFTA (N=543) |
| Injection site reaction* | 6 | 17 |
| Arthralgia | 11 | 13 |
| Pain in extremity | 5 | 6 |
| Myalgia | 2 | 6 |
| Edema peripheral | 2 | 6 |
| Paresthesia | 2 | 5 |
| Hypoesthesia | 2 | 4 |
| Rash | 2 | 4 |
| Dyspepsia | 1 | 2 |
| Musculoskeletal pain | 1 | 2 |
| Pain | 1 | 2 |
| Pruritus | 1 | 2 |
| Vomiting | 0 | 3 |
| Musculoskeletal stiffness | 0 | 2 |
| Blood creatine phosphokinase increased | 0 | 1 |
| Carpal tunnel syndrome | 0 | 1 |
| Joint swelling | 0 | 1 |
| Muscle strain | 0 | 1 |
| Night sweats | 0 | 1 |
| Palpitations | 0 | 1 |
| * Injection site reaction includes: Injection site erythema, Injection site pruritus, Injection site rash, Injection site urticaria, Injection site pain, Injection site swelling, Injection site irritation, Injection site hemorrhage. | ||
In the EGRIFTA clinical trials, mean baseline HbA1c was 5.3% among patients in both the EGRIFTA and placebo groups. Patients receiving EGRIFTA had an increased risk of developing diabetes (HbA1c level ≥ 6.5%) compared with placebo (5% vs. 1%), with a hazard ratio of 3.3 (CI 1.4, 9.6).
As with all therapeutic proteins and peptides, there is a potential for development of anti-EGRIFTA antibodies. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, methodology, sample handling, timing of sample collection, concomitant medication and underlying disease. For these reasons, comparison of the incidence of antibodies to EGRIFTA with the incidence of antibodies to other products may be misleading.
In the clinical trials with the EGRIFTA 1 mg/vial formulation, anti-tesamorelin IgG antibodies were detected in 50% of patients who received EGRIFTA for 26 weeks and 47% of patients who received EGRIFTA for 52 weeks. In the subset of patients with hypersensitivity reactions, antitesamorelin IgG antibodies were detected in 85%. Cross-reactivity to endogenous growth hormonereleasing hormone (GHRH) was observed in approximately 60% of patients who developed antitesamorelin antibodies. Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue (VAT) and IGF-1 response. In a group of patients who had antibodies to tesamorelin after 26 weeks of treatment (56%) and were re-assessed 6 months later, after stopping EGRIFTA treatment, 18% were still antibody positive.
Neutralizing antibodies to tesamorelin and human GHRH (hGHRH) were detected in vitro at Week 52 in 10% and 5% of EGRIFTA-treated patients, respectively. Changes in VAT and IGF-1 levels in patients with or without in vitro neutralizing antibodies were comparable.
Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see CLINICAL PHARMACOLOGY].
EGRIFTA SV stimulates GH production. Published data indicate that GH may modulate cytochrome P450 (CYP450) mediated antipyrine clearance. These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). Monitor patients for potential interactions when administering EGRIFTA SV in combination with other drugs known to be metabolized by CYP450 liver enzymes.
GH inhibits 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1), a microsomal enzyme required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. EGRIFTA SV stimulates GH production; therefore, patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. Patients treated with cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.
Included as part of the PRECAUTIONS section.
Carefully consider the decision to start treatment with EGRIFTA SV based on the increased background risk of malignancies in HIV-positive patients.
EGRIFTA SV induces the release of endogenous growth hormone (GH), a known growth factor. Do not treat patients with active malignancy with EGRIFTA SV [see CONTRAINDICATIONS].
For patients with a history of non-malignant neoplasms, initiate EGRIFTA SV therapy after careful evaluation of the potential benefit of treatment. For patients with a history of treated and stable malignancies, initiate EGRIFTA SV therapy only after careful evaluation of the potential benefit of treatment relative to the risk of re-activation of the underlying malignancy. Discontinue EGRIFTA SV if there is any evidence of recurrent malignancy.
EGRIFTA SV stimulates GH production and increases serum IGF-1, a growth factor. The effects of prolonged elevations in IGF-1 levels are unknown. Monitor IGF-1 levels during EGRIFTA SV therapy. Consider discontinuing EGRIFTA SV in patients with persistent elevations of IGF-1 levels (e.g., >3 SDS), particularly if the efficacy response is not robust.
Among patients who received EGRIFTA for 26 weeks, 47% had IGF-1 levels greater than 2 standard deviation scores (SDS), and 36% had SDS >3, with this effect seen as early as 13 weeks of treatment. Among those patients who remained on EGRIFTA for a total of 52 weeks, at the end of treatment, 34% had IGF-1 SDS >2 and 23% had IGF-1 SDS >3.
Fluid retention may occur during EGRIFTA SV therapy and is thought to be related to the induction of GH secretion. This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g. edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment.
EGRIFTA SV treatment can result in glucose intolerance. During clinical trials, the percentages of patients with elevated HbA1c (≥ 6.5%) from baseline to Week 26 were 5% and 1% in the EGRIFTA and placebo groups, respectively. An increased risk of developing diabetes with EGRIFTA (HbA1c level ≥ 6.5%) relative to placebo was observed [intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6)].
Evaluate glucose status prior to initiating EGRIFTA SV. Monitor all patients treated with EGRIFTA SV periodically to diagnose those who develop impaired glucose tolerance or diabetes. If patients treated with EGRIFTA SV develop glucose intolerance or diabetes, consider discontinuing EGRIFTA SV in patients who do not show a clear efficacy response.
EGRIFTA SV increases IGF-1, monitor patients with diabetes who are receiving treatment with EGRIFTA SV at regular intervals for potential development or worsening of retinopathy.
Hypersensitivity reactions occurred in 4% of patients treated with EGRIFTA in clinical trials. Reactions included pruritus, erythema, flushing, urticaria, and rash. In cases of suspected hypersensitivity reactions, advise patients to seek prompt medical attention and immediately discontinue treatment with EGRIFTA SV.
EGRIFTA SV treatment may cause injection site reactions, including injection site erythema, pruritus, pain, irritation, and bruising. The incidence of injection site reactions was 25% in EGRIFTA treated patients and 14% in placebo-treated patients during the first 26 weeks of treatment in clinical trials. Rotate injection sites to different areas of the abdomen to decrease injection site reactions [see DOSAGE AND ADMINISTRATION].
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of growth hormone. EGRIFTA SV is a growth hormone-releasing hormone (GHRH) and since it stimulates growth hormone production, consider discontinuing EGRIFTA SV in critically ill patients.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Inform patients about the increased background risk of malignancies in HIV-positive patients and for patients with a history of neoplasms, inform them about the risk of malignancy reoccurrence [see WARNINGS AND PRECAUTIONS].
Inform patients that treatment with EGRIFTA SV increases IGF-1 levels and that they will need periodic monitoring of their IGF-1 levels [see WARNINGS AND PRECAUTIONS].
Inform patients that treatment with EGRIFTA SV may cause fluid retention, resulting in adverse reactions including edema, arthralgia, and carpal tunnel syndrome [see WARNINGS AND PRECAUTIONS].
Inform patients that treatment with EGRIFTA SV may result in glucose intolerance or diabetes mellitus. Advise patients that they will need to be monitored to see if impaired glucose tolerance or diabetes mellitus develops, and that if they have pre-existing diabetes mellitus, they may need adjustments to their anti-diabetic medications [see WARNINGS AND PRECAUTIONS].
Inform patients that hypersensitivity reactions (e.g., rash, urticaria) may occur during treatment with EGRIFTA SV. Advise patients to seek prompt medical attention and to immediately discontinue treatment with EGRIFTA SV if a reaction occurs [see WARNINGS AND PRECAUTIONS].
Inform patients that injection site reactions may occur with EGRIFTA SV, including injection site erythema, pruritus, pain, irritation, and bruising. Advise patients to rotate the site of injection to reduce the risk of injection site reactions [see WARNINGS AND PRECAUTIONS].
Advise women to discontinue EGRIFTA SV if pregnancy occurs, as the drug offers no known benefit to pregnant women and could result in fetal harm [see CONTRAINDICATIONS and Use In Specific Populations].
Because of both the potential for HIV-1 infection transmission and serious adverse reactions in nursing infants, mothers receiving EGRIFTA SV should be instructed not to breastfeed [see Use In Specific Populations].
Counsel patients that they should never share an EGRIFTA SV syringe with another person, even if the needle is changed. Sharing of syringes or needles between patients may pose a risk of transmission of infection.
Life-time carcinogenicity studies in rodents have not been conducted with tesamorelin acetate. No potential mutagenicity of tesamorelin acetate was revealed in a battery of tests including induction of gene mutations in bacteria (the Ames test), gene mutations in mammalian cells grown in vitro (hamster CHOK1 cells), and chromosomal damage in intact animals (bone marrow cells in mice). There was no effect on fertility in male or female rats following administration of tesamorelin acetate at doses up to 0.6 mg/kg (approximately equal to clinical exposure) for 28 days in males or 14 days in females.
EGRIFTA SV is contraindicated in pregnant women because modifying visceral adipose tissue offers no benefit in pregnant women and could result in fetal harm [see Clinical Considerations and CONTRAINDICATIONS]. Administration of tesamorelin acetate to rats during organogenesis resulted in hydrocephaly in offspring at a dose of approximately two and four times the clinical dose, based on measured drug exposure (AUC). If EGRIFTA SV is used during pregnancy, or if the patient becomes pregnant while taking it, discontinue EGRIFTA SV.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Disease-Associated Maternal And/Or Embryo/Fetal Risk
During pregnancy, visceral adipose tissue increases due to normal metabolic and hormonal changes. Modifying pregnancy-associated physiologic changes in visceral adipose tissue with EGRIFTA SV offers no known benefit and could result in fetal harm.
Animal Data
Tesamorelin acetate administration to rats during organogenesis and lactation resulted in hydrocephaly in offspring at a dose of approximately two and four times the clinical dose, respectively, based on measured drug exposure (AUC). Actual animal dose was 1.2 mg/kg. During organogenesis, lower doses approximately 0.1 to 1 times the clinical dose caused delayed skull ossification in rats. Actual animal doses were 0.1 to 0.6 mg/kg. No adverse developmental effects occurred in rabbits using doses up to approximately 500 times the clinical dose.
The Centers for Disease Control and Prevention recommend that HIV-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection. There are no data on the presence of tesamorelin in human milk, the effects on the breastfed child, or the effects on milk production. Because of both the potential for (1) HIV-1 infection transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive patients), and (3) any possible adverse effects of tesamorelin, mothers should not breastfeed if they receive EGRIFTA SV.
The safety and effectiveness of EGRIFTA SV in pediatric patients have not been established.
In pediatric patients with open epiphyses, treatment with EGRIFTA SV may result in linear growth acceleration and excessive growth. EGRIFTA SV is not indicated for use in pediatric patients with open or closed epiphyses.
There is no information on the use of EGRIFTA SV in patients greater than 65 years of age.
EGRIFTA SV has not been studied in patients with renal impairment.
EGRIFTA SV has not been studied in patients with hepatic impairment.
No Information provided
EGRIFTA SV is contraindicated in patients with:
In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF [see CLINICAL PHARMACOLOGY].
Growth hormone-releasing factor (GHRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.
Tesamorelin stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels. No clinically significant changes in the levels of other pituitary hormones, including thyroidstimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in patients receiving EGRIFTA in clinical trials.
The absolute bioavailability of tesamorelin after subcutaneous administration of a 2 mg dose of EGRIFTA (1 mg/vial formulation) was determined to be less than 4% in healthy adult subjects.
Single and multiple dose pharmacokinetics have been characterized in healthy subjects and HIV-infected patients without lipodystrophy using a 2 mg dose of EGRIFTA (1 mg/vial formulation). Tesamorelin mean extent of absorption (AUC) was 34% higher in HIV-infected patients than healthy subjects. Tesamorelin peak plasma concentration (Cmax) was similar in HIV-infected patients and healthy subjects. The median peak plasma tesamorelin concentration (Tmax) was 0.15 h in both populations.
Following single dose of subcutaneous administration of 1.4 mg of EGRIFTA SV (2 mg/vial formulation) in healthy subjects, the mean [coefficient of variation (CV)] AUC0-inf was 889.1 (57%) pg.h/mL. The mean (CV) Cmax value was 2956.1 (47%) pg/mL and the median Tmax was 0.15 h.
The systemic exposure (Cmax and AUCs) of tesamorelin is similar between the 1.4 mg dose of EGRIFTA SV (2 mg/vial formulation) and the 2 mg dose of EGRIFTA (1 mg/vial formulation).
The mean volume of distribution (±SD) of tesamorelin following a single subcutaneous administration of the 1.4 mg dose of EGRIFTA SV (2 mg/vial formulation) was 4.8 ± 1.9 L/kg in healthy subjects.
No formal metabolism studies have been performed in humans.
Mean elimination half-life (t½) of tesamorelin was 8 minutes in healthy subjects after single dose subcutaneous administration of the 1.4 mg of EGRIFTA SV (2 mg/vial formulation).
Pharmacokinetics of tesamorelin in patients with renal or hepatic impairment, in pediatric patients, or in elderly patients has not been established.
The effect of multiple dose administration of EGRIFTA on the pharmacokinetics of simvastatin and simvastatin acid was evaluated in healthy subjects. Co-administration with simvastatin (a CYP3A substrate) resulted in 8% decrease in extent of absorption (AUCinf) and 5% increase in rate of absorption (Cmax) of simvastatin. For simvastatin acid there was a 15% decrease in AUC and 1% decrease in Cmax [see DRUG INTERACTIONS].
The effect of multiple dose administration of EGRIFTA on the pharmacokinetics of ritonavir was evaluated in healthy subjects. Co-administration with ritonavir resulted in 9% decrease in AUCinf and 11% decrease in Cmax of ritonavir [see DRUG INTERACTIONS].
The safety and effectiveness of EGRIFTA SV (2 mg/vial formulation) has been established based on adequate and well controlled studies with EGRIFTA (1 mg/vial formulation), as well as a demonstration of comparable bioavailability between the 1.4 mg EGRIFTA SV dose (2 mg/vial formulation) and the 2 mg EGRIFTA dose (1 mg/vial formulation) [see CLINICAL PHARMACOLOGY].
Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in HIVinfected patients with lipodystrophy and excess abdominal fat (abdominal lipohypertrophy). Study 1 and Study 2 consisted of a 26-week Main Phase and a 26-week Extension Phase, respectively. Main inclusion criteria were age 18 to 65 years, a waist circumference ≥95 cm (37.4 inches) and a waist-tohip ratio ≥0.94 for men and ≥94 cm (37.0 inches) and ≥0.88 for women, respectively, and fasting blood glucose (FBG) <150 mg/dL (8.33 mmol/L). Main exclusion criteria included BMI ≤ 20 kg/m², type 1 diabetes mellitus, type 2 diabetes mellitus, previous treatment with insulin or with oral hypoglycemic or insulin-sensitizing agents, history of malignancy, and hypopituitarism. Patients were on a stable antiretroviral regimen for at least 8 weeks prior to randomization. Patients meeting the inclusion/exclusion criteria were randomized in a 2:1 ratio to receive a 2 mg dose of EGRIFTA (1 mg/vial formulation) or placebo subcutaneously daily for 26 weeks. The primary efficacy assessment for each of these studies was the percent change from baseline to Week 26 in visceral adipose tissue (VAT), as assessed by computed tomography (CT) scan at L4-L5 vertebral level. Secondary endpoints included changes from baseline in patient-reported outcomes related to body image, triglycerides, ratio of total cholesterol to HDL cholesterol, IGF-1 levels, and safety parameters. Other endpoints included changes from baseline in waist circumference, abdominal subcutaneous tissue (SAT), trunk fat, and lean body mass. In both studies, EGRIFTA-treated patients completing the 26-week treatment period were re-randomized to blinded therapy with either daily placebo or a 2 mg dose of EGRIFTA (1 mg/vial formulation) for an additional 26-week treatment period (Extension Phase) in order to assess maintenance of VAT reduction and to gather long-term safety data. For inclusion in the Extension Phase studies, subjects must have completed the Main Phase with FBG ≤ 150 mg/dL.
Study 1 (NCT 00123253)
This study randomized 412 HIV-infected patients with lipodystrophy and excess abdominal fat to receive either a 2 mg dose of EGRIFTA (1 mg/vial formulation) (N=273) or placebo (N=137). At baseline for the two groups combined, mean age was 48 years; 86% were male; 75% were white, 14% were Black/African American, and 8% were Hispanic; mean weight was 90 kg; mean BMI was 29 kg/m²; mean waist circumference was 104 cm; mean hip circumference was 100 cm; mean VAT was 176 cm²; mean CD4 cell count was 606 cells/mm³; 69% had undetectable viral load (<50 copies/mL); and 33.7% randomized to EGRIFTA and 36.6% randomized to placebo had impaired glucose tolerance, while 5.6% randomized to EGRIFTA and 6.7% randomized to placebo had diet-controlled diabetes mellitus. The twenty-six week completion rate in Study 1 was 80%.
Study 2 (NCT 00435136)
This study randomized 404 HIV-infected patients with lipodystrophy and excess abdominal fat to receive either a 2 mg dose of EGRIFTA (1 mg/vial formulation) (N=270) or placebo (N=126). At baseline for the two groups combined, mean age was 48 years; 84% were male; 77% were white, 12% were Black/African American, and 9% were Hispanic; mean weight was 88 kg; mean BMI was 29 kg/m²; mean waist circumference was 105 cm; mean hip circumference was 100 cm; mean VAT was 189 cm²; mean CD4 cell count was 592 cells/mm³; 83% had undetectable viral load (<50 copies/mL); and 44% randomized to EGRIFTA and 40% randomized to placebo had impaired glucose tolerance, while 9% randomized to EGRIFTA and 10% randomized to placebo had diet-controlled type 2 diabetes mellitus. The twenty-six week completion rate in Study 2 was 74%.
Results for the Main Phases of Studies 1 and 2 are presented in Tables 2 and 3.
Table 2: Changes from Baseline to Week 26 in Visceral Adipose Tissue (cm²) by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)
| MAIN PHASE (Baseline-Week 26) | ||||
| Study 1 | Study 2 | |||
| 2 mg EGRIFTA (1 mg/vial) (N=273) | Placebo (N=137) | 2 mg EGRIFTA (1 mg/vial) (N=270) | Placebo (N=126) | |
| Baseline (cm²) | 178 (77) | 171 (77) | 186 (87) | 195 (95) |
| Change (cm²) | -27 | 4 | -21 | -0 |
| Mean treatment difference (95% CI) | -31 (-39,-24) | -21 (-29,-12) | ||
| Mean change (%)1 | -18 | 2 | -14 | -2 |
| Mean treatment difference (95% CI)1 | -20 (-24, -15) | -12 (-16, -7) | ||
| Baseline data are expressed as mean (SD); Change refers to least-squares mean (LSM); CI: confidence interval. 1 Results derived from the statistical model: Ln(VAT Week 26/VAT Baseline) = Ln(VAT Baseline) + treatment Group | ||||
Table 3: Changes from Baseline to Week 26 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)
| MAIN PHASE (Baseline-Week 26) | |||||
| Study 1 | Study 2 | ||||
| 2 mg EGRIFTA (1 mg/vial) (N=273) | Placebo (N=137) | 2 mg EGRIFTA (1 mg/vial) | Placebo (N=126) | ||
| IGF-1 (ng/mL) | Baseline | 161 (59) | 168 (75) | 146 (66) | 149 (59) |
| Change | 107 | -15 | 108 | 3 | |
| Mean treatment difference (95% CI) | 122 (101, 141) | 105 (85, 126) | |||
| IGFBP-3 (mg/L) | Baseline | 3 (1) | 3 (1) | 3 (1) | 3 (1) |
| Change | 0.4 | -0.2 | 0.8 | -0.0 | |
| Mean treatment difference (95% CI) | 0.6 (0.5, 0.8) | 0.8 (0.5, 1.0) | |||
| Weight (kg) | Baseline | 90 (14) | 90 (14) | 89 (14) | 87 (16) |
| Change | -0.4 | 0.0 | 0.5 | 0.3 | |
| Mean treatment difference (95% CI) | -0.4 (-1.3, 0.5) | 0.2 (-0.7, 1.3) | |||
| Waist circumference (cm) | Baseline | 104 (10) | 105 (9) | 105 (9) | 105 (9) |
| Change | -3 (5) | -1 (4) | -2 (5) | -1 (5) | |
| Mean treatment difference (95% CI) | -2 (-2.8, -0.9) | -1 (-2.5, -0.3) | |||
| Baseline data are expressed as mean (SD); Change refers to least-squares mean (LSM); CI: confidence interval. | |||||
At Week 26, treatment with a 2 mg dose of EGRIFTA (1 mg/vial formulation) resulted in a reduction from baseline in mean trunk fat of 1.0 kg in Study 1 and 0.8 kg in Study 2, respectively (compared with an increase of 0.4 kg in Study 1 and of 0.2 kg in Study 2, respectively, in patients receiving placebo). Treatment with EGRIFTA resulted in an increase from baseline in mean lean body mass of 1.3 kg in Study 1 and of 1.2 kg in Study 2, respectively (compared with a decrease of 0.2 kg in Study 1 and of 0.03 kg in Study 2, respectively, in patients receiving placebo).
Patients rated the degree of distress associated with their belly appearance on a 9-point rating scale that was then transformed to a score from 0 (extremely upsetting and distressing) to 100 (extremely encouraging). A score of 50 indicated neutral (no feeling either way). A positive change from baseline score indicated improvement, i.e., less distress.
The cumulative distribution of response (change from baseline to 26 weeks) is shown in Figure 1 for both treatment groups. A curve shifted to the right on this scale indicates a greater percentage of patients reporting improvement.
Figure 1: Cumulative Distribution of Response for Belly Appearance Distress
 |
In the double-blind Extension Phase, patients on a 2 mg dose of EGRIFTA (1 mg/vial formulation) completing the 26-week Main Phase were re-randomized to receive a 2 mg dose of EGRIFTA (1 mg/vial formulation) or placebo.
Study 1 (NCT 00123253)
This study re-randomized 207 HIV-infected patients with lipodystrophy who completed a 2 mg dose of EGRIFTA (1 mg/vial formulation) treatment in the Main Phase to receive either EGRIFTA (N=154) or placebo (N=50) for an additional 26-week duration (3:1 randomization ratio). At baseline (Week 26) for the two groups combined, mean age was 48 years; 88% were male; 78% were white, 12% were Black/African American, and 8% were Hispanic; mean weight was 90 kg; mean BMI was 29 kg/m²; mean waist circumference was 102 cm; mean hip circumference was 100 cm; mean VAT was 145 cm²; mean CD4 cell count was 639 cells/mm³; 68% had undetectable viral load (<50 copies/mL); and for those EGRIFTA-treated patients completing the 26-week treatment period that were re-randomized to EGRIFTA (T-T group) or re-randomized to placebo, 37% and 32%, respectively, had impaired glucose tolerance, while 2% re-randomized to EGRIFTA and 6% re-randomized to placebo had diet-controlled type 2 diabetes mellitus. The completion rate for patients randomized into the extension phase of Study 1 was 83%.
Study 2 (NCT 00435136)
This study re-randomized 177 HIV-infected patients with lipodystrophy who completed EGRIFTA treatment in the Main Phase to receive either a 2 mg dose of EGRIFTA (1 mg/vial formulation) (N=92) or placebo (N=85) for an additional 26-week duration (1:1 randomization ratio). At baseline (Week 26) for the two groups combined, mean age was 48 years; 90% were male; 84% were white, 9% were Black/African American, and 7% were Hispanic; mean weight was 89 kg; mean BMI was 28 kg/m²; mean waist circumference was 105 cm; mean hip circumference was 100 cm; mean VAT was 172 cm²; mean CD4 cell count was 579 cells/mm³; 82% had undetectable viral load (<50 copies/mL); and for those EGRIFTA-treated patients completing the 26-week treatment period that were re-randomized to EGRIFTA (T-T group) or re-randomized to placebo, 49% and 51%, respectively, had impaired glucose tolerance, while 4% re-randomized to EGRIFTA and 13% re-randomized to placebo had diet-controlled diabetes mellitus. The completion rate for patients randomized into the extension phase of Study 2 was 81%.
Results for the Extension Phases of Studies 1 and 2 are presented in Tables 4 and 5.
Table 4: Changes from Week 26 Baseline to Week 52 in Visceral Adipose Tissue (cm²) by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)
| EXTENSION PHASE (Week 26-52) | ||||
| Study 1 | Study 2 | |||
| T-T1 (Week 26-52) (N=154) | T-P2 (Week 26-52) (N=50) | T-T1 (Week 26-52) (N=92) | T-P2 (Week 26-52) (N=85) | |
| Week 26 (cm²) | 145 (72) | 144 (72) | 166 (89) | 177 (88) |
| Change (cm²) | 3 | 25 | -11 | 24 |
| Mean treatment difference (95% CI) | -22 (-34, -10) | -35 (-48, -22) | ||
| Mean change (%)3 | 0 | 22 | -5 | 16 |
| Mean treatment difference (95% CI)3 | -17 (-24, -10) | -18 (-24, -11) | ||
| Week 26 baseline data are expressed as mean (SD). Change refers to least-squares mean (LSM); CI: confidence interval. 1T-T = tesamorelin for Weeks 0-26 and tesamorelin for Weeks 26-52 2T-P = tesamorelin for Weeks 0-26 and placebo for Weeks 26-52 3Results derived from the statistical model: Ln(VAT Week 52/Week 26) = Ln(Week 26 VAT) + treatment group | ||||
Figure 2 shows the percent change in VAT from baseline (Week 0) over time until 52 weeks in completer patients.
Figure 2: Percent Change from Baseline in VAT over Time
 |
Data in Figure 2 are expressed as mean values. T-T (tesamorelin to tesamorelin) refers to the group of patients who received tesamorelin for Weeks 0-26 and were re-randomized to tesamorelin for Weeks 26-52. T-P (tesamorelin to placebo) refers to the group of patients who received tesamorelin for Weeks 0-26 and were re-randomized to placebo for Weeks 26-52. P-T (placebo to tesamorelin) refers to the group of patients who received placebo for Weeks 0-26 and were switched to tesamorelin (treated open label) for Weeks 26-52.
Table 5: Changes from Week 26 Baseline to Week 52 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward)
| EXTENSION PHASE (Weeks 26-52) | |||||
| Study 1 | Study 2 | ||||
| T-T1 (Week 26-52) (N=154) | T-P2 (Week 26-52) (N=50) | T-T1 (Week 26-52) (N=92) | T-P2 (Week 2652) (N=85) | ||
| IGF-1 (ng/mL) | Week 26 | 291 (124) | 281 (105) | 280 (134) | 269 (110) |
| Change | -59 | -137 | -25 | -135 | |
| Mean treatment difference (95% CI) | 78 (50, 106) | 110 (87, 134) | |||
| IGFBP-3 (mg/L) | Week 26 | 3 (1) | 3 (1) | 3 (1) | 3 (1) |
| Change | -0.2 | -0.5 | -0.3 | -0.9 | |
| Mean treatment difference (95% CI) | 0.3 (-0.0, 0.6) | 0.6 (0.3, 0.9) | |||
| Weight (kg) | Week 26 | 89 (14) | 92 (17) | 89 (13) | 90 (14) |
| Change | 0.2 | 0.6 | -0.5 | 0.1 | |
| Mean treatment difference (95% CI) | -0.4 (-2, 1) | -0.6 (-2, 1) | |||
| Waist circumference (cm) | Week 26 | 101 (10) | 102 (12) | 101 (9) | 103 (11) |
| Change | -0.2 | 2.4 | -1.1 | 0.2 | |
| Mean treatment difference (95% CI) | -2.6 (-4, -1) | -1.3 (-2, 0) | |||
| Week 26 baseline data are expressed as mean (SD); Change refers to least-squares mean (LSM); CI: confidence interval. 1T-T = tesamorelin for Week 0-26 and tesamorelin for Week 26-52 2T-P = tesamorelin for Week 0-26 and placebo for Week 26-52 | |||||
Patients treated with a 2 mg dose of EGRIFTA (1 mg/formulation) for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively).
EGRIFTA SV™
(eh-GRIF-tuh ESS-vee)
(tesamorelin for injection) for subcutaneous use 2 mg vial
Read the Patient Information that comes with EGRIFTA SV before you start to take EGRIFTA SV and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment.
What is EGRIFTA SV?
The long-term safety of EGRIFTA SV on the heart and blood vessels (cardiovascular) is not known.
EGRIFTA SV is not for weight loss management.
It is not known whether taking EGRIFTA SV helps improve how well you take (compliance with) antiretroviral medicines.
It is not known if EGRIFTA SV is safe and effective in children.
EGRIFTA SV is not recommended to be used in children with open or closed bone growth plates (epiphyses).
Who should not use EGRIFTA SV?
Do not use EGRIFTA SV if you:
What should I tell my healthcare provider before using EGRIFTA SV?
Before using EGRIFTA SV, tell your healthcare provider about all of your medical conditions , including if you:
Tell your healthcare provider about all the medicines you take, including prescription and overthe- counter medicines, vitamins, and herbal supplements.
How should I use EGRIFTA SV?
What are the possible side effects of EGRIFTA SV?
EGRIFTA SV may cause serious side effects, including:
The most common side effects of EGRIFTA SV include:
These are not all the possible side effects of EGRIFTA SV. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088.
You may also report side effects to THERA patient support™ toll-free at 1-833-23THERA (1-833-238-4372).
How should I store EGRIFTA SV 2 mg vials, Sterile Water for Injection, syringes and needles ?
Keep EGRIFTA SV and all medicines out of the reach of children.
General information about the safe and effective use of EGRIFTA SV.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use EGRIFTA SV for a condition for which it was not prescribed. Do not give EGRIFTA SV to other people, even if they have the same symptoms you have. It may harm them.
You can ask your healthcare provider or pharmacist for information about EGRIFTA SV that is written for health professionals.
What are the ingredients in EGRIFTA SV?
Active ingredient: tesamorelin acetate
Inactive ingredients : mannitol, sucrose, histidine, polysorbate 20
Instructions for Use
EGRIFTA SV ™
(eh-GRIF-tuh ESS-vee)
(tesamorelin for injection) for subcutaneous use 2 mg/vial
This Instructions for Use contains step-by-step information on how to use the 2 mg vial of EGRIFTA SV. Each 2 mg vial of EGRIFTA SV must be mixed with 0.5 mL of the Sterile Water for Injection provided in the Injection Box given to you by the pharmacy. Use only one EGRIFTA SV 2 mg vial from the Medication Box to prepare your dose. The recommended dose of EGRIFTA SV is 1.4 mg (0.35 mL).
Be sure that you read, understand, and follow this Instructions for Use before using EGRIFTA SV. Your healthcare provider should show you how to mix and inject EGRIFTA SV before you inject it for the first time. Ask your healthcare provider if you have any questions.
Keep this Instructions for Use in case you need to look at it again later.
Important information for use of EGRIFTA SV
Preparing for your EGRIFTA SV injection
Step 1: Find a well-lit, clean, and flat surface, such as a table.
Step 2: Gather your supplies:
For each injection using EGRIFTA SV 2 mg vial you will need: (See Figure A)
Figure A
Injection Box
 |
Step 3: Take out the following from the Injection Box:
Step 4: Take 1 vial of EGRIFTA SV 2 mg from the Medication Box.
Step 5: Prepare to use your supplies:
How to mix EGRIFTA SV 2 mg vial
Step 1: Place a 1“ 20-gauge needle used for mixing, with its protective needle cap in place, onto a 1 mL syringe. Hold the syringe firmly and twist the needle cap clockwise (to the right) until it closes securely. (See Figure B)
Figure B
 |
Step 2: Carefully remove the protective needle cap by pulling it straight off. Do not twist the needle cap.
Insert the needle through the rubber stopper of the Sterile Water for Injection bottle. (See Figure C)
Figure C
 |
Step 3: With the needle still in the Sterile Water for Injection bottle, turn the bottle and syringe upside down.
Pull back the plunger until the Sterile Water reaches the 0.5 mL mark on the syringe. (See Figure D)
Figure D
 |
Step 4: Remove the syringe with needle attached from the Sterile Water bottle.
Insert the needle into the rubber stopper of the EGRIFTA SV 2 mg vial.
With the needle at a slight angle, slowly push the plunger of the syringe all the way down so that the Sterile Water goes down the inside wall of the EGRIFTA SV 2 mg vial instead of directly onto the powder to avoid foaming. (See Figure E)
Figure E
 |
Step 5: Remove the needle from the EGRIFTA SV 2 mg vial (see Figure F) and throw away the syringe and needle. (See “How should I dispose of the used syringes, needles, bottles and vials ?”)
Figure F
 |
Step 6: Roll the EGRIFTA SV 2 mg vial gently in your hands for 30 seconds, until the Sterile Water and EGRIFTA SV powder are mixed well. Do not shake the vial. (See Figure G)
Figure G
 |
Note:
Step 7: Place a new unused 1“ 20-gauge needle used for mixing, with its protective needle cap in place, onto a new unused 1 mL syringe. Hold the syringe firmly and twist the needle cap clockwise (to the right) until it closes securely. (See Figure H)
Figure H
 |
Step 8: Carefully remove the protective needle cap by pulling it straight off. Do not twist the needle cap.
Do not throw away the needle cap.
Insert the needle through the rubber stopper of the EGRIFTA SV 2 mg vial. (See Figure I)
Figure I
 |
Step 9: With the needle still in the EGRIFTA SV 2 mg vial, turn the vial and syringe upside down. Pull the syringe back until you see just the tip of the needle going through the rubber stopper. Pull back on the plunger of the syringe until all of the liquid inside the vial is in the syringe. The medicine should be at around the 0.4 mL mark on the syringe. (See Figure J)
Figure J
 |
Step 10: Remove the needle from the vial. (See Figure K)
Figure K
 |
Step 11: Place the protective needle cap on its side on a clean flat surface. Without touching the needle, hold the syringe and slide the needle carefully into the needle cap. (See Figure L).
Figure L
 |
Step 12: Push the protective needle cap all the way in or until it snaps shut (See Figure M). Do not touch the needle cap until it covers the needle completely.
Figure M
 |
Step 13: With the protective needle cap securely on the needle, remove the needle by holding the syringe firmly and twisting the needle cap counterclockwise (to the left). (See Figure N)
Throw away the needle. (See “How should I dispose of the used syringes, needles, bottles and vials ?”)
Figure N
 |
Step 14: Place a ½“ 30-gauge needle to be used for your injection, with its protective needle cap and pink needle shield in place, onto the syringe. Hold the syringe firmly and twist the needle cap and pink needle shield clockwise (to the right) until it closes securely. (See Figure O)
Figure O
 |
Where do I inject EGRIFTA SV 2 mg vial?
Inject EGRIFTA SV into the stomach-area (abdomen). (See Figure P)
Figure P
 |
How to inject your 1.4 mg dos e of EGRIFTA SV
Do not remove the needle cap until you are ready to inject.
Step 1: Hold the syringe with the needle facing up. Pull the pink needle shield down away from the white protective needle cap.
Carefully remove the needle cap by pulling it straight off the needle. Do not twist the needle cap. (See Figure Q)
Do not touch the needle.
Figure Q
 |
Step 2: Tap the syringe gently with your finger to force any air bubbles to rise to the top. Slowly push up on the plunger to remove any air and bubbles and until the medicine in the syringe is at the 0.35 mL mark of the syringe. (See Figure R)
Figure R
 |
Step 3: Clean the injection site you have selected with an alcohol pad and let it dry.
Hold the syringe in one hand. With your other hand, gently pinch a fold of skin at your cleaned injection site. Hold the skin between your thumb and fingers. (See Figure S)
Figure S
 |
Step 4: Hold the syringe at a 90 degree angle to the skin.
With a quick, dart-like motion, insert the needle straight into the skin. Most of the needle should go beneath the skin. (See Figure T)
Figure T
 |
Step 5: Remove your hand from the pinched area of skin after the needle is inserted. Be careful not to remove the needle from the skin.
Step 6: Slowly push the plunger of the syringe all the way down until all of the medicine in the syringe has been injected. (See Figure U)
Figure U
 |
Pull the needle out of your skin. Be careful to pull the needle out at the same angle as it was inserted.
Step 7: While holding the syringe in one hand, gently press the pink needle shield against a hard, flat surface until you hear a “click” and the injection needle is covered by the pink needle shield. (See Figure V)
Figure V
 |
How should I dispose of the used syringes, needles, bottles and vials ?
If you have any questions, call your healthcare provider. You can call THERA patient support™ toll free at 1-833-23THERA (1-833-238-4372) or visit the EGRIFTA SV website at: www.EGRIFTASV.com for more information.
How should I store EGRIFTA SV 2 mg vials, Sterile Water for Injection, syringes and needles ?
Keep EGRIFTA SV and all medicines out of the reach of children.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
